Analyst Price Targets — VSTM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 4:58 pm | — | Mizuho Securities | $13.00 | $6.51 | TheFly | Verastem price target lowered to $13 from $14 at Mizuho |
| August 7, 2026 11:33 am | — | Guggenheim | $12.00 | $5.91 | TheFly | Verastem price target lowered to $12 from $14 at Guggenheim |
| July 7, 2026 11:31 am | — | RBC Capital | $14.00 | $4.46 | TheFly | Verastem price target lowered to $14 from $15 at RBC Capital |
| June 24, 2026 1:37 pm | Leonid Timashev | RBC Capital | $15.00 | $4.33 | StreetInsider | RBC Capital on Verastem (VSTM): 'We think shares are undervalued' |
| June 23, 2026 12:34 pm | — | Jefferies | $8.00 | $4.32 | TheFly | Verastem price target lowered to $8 from $15 at Jefferies |
| May 8, 2026 11:26 am | — | BTIG | $18.00 | $5.66 | TheFly | Verastem price target lowered to $18 from $19 at BTIG |
| May 8, 2026 11:04 am | — | Industrial Alliance Securities | $18.00 | $5.66 | TheFly | Verastem price target raised to $18 from $16 at Alliance Global |
| March 5, 2026 3:06 pm | Clara Dong | Jefferies | $19.00 | $6.18 | StreetInsider | Jefferies Reiterates Buy Rating on Verastem (VSTM); "catalyst-rich 2026" |
| February 19, 2026 12:18 pm | — | Mizuho Securities | $18.00 | $5.71 | TheFly | Verastem price target raised to $18 from $15 at Mizuho |
| October 29, 2025 12:51 pm | — | Mizuho Securities | $15.00 | $8.85 | TheFly | Verastem price target raised to $15 from $14 at Mizuho |
Latest News for VSTM
Verastem is evolving from a speculative biotech into a commercially validated precision oncology company, leveraging AVMAPKI FAKZYNJA revenue to fund KRAS G12D programs. VSTM's AVMAPKI FAKZYNJA launch demonstrates strong product-market fit, with $43.7M H1 2026 revenue and growing prescriber adoption in a rare disease market. The October 2026 VS-7375 data update is a pivotal catalyst; positive results could unlock…
Shares of Verastem, Inc. (NASDAQ: VSTM - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and one has
Verastem NASDAQ: VSTM reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in commercial performance.
Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
Verastem (VSTM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.39 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VSTM.
U.S. House Trading
No House trades found for VSTM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.